```html

Wegener’s Granulomatosis (Nasal) – A Comprehensive Patient Guide

Overview

Wegener’s Granulomatosis (more formally called Granulomatosis with Polyangiitis – GPA) is a rare, systemic autoimmune disease that causes inflammation of small‑ and medium‑sized blood vessels (vasculitis). When the disease primarily involves the nose, sinuses, and upper airways, it is often referred to as “nasal GPA.”

• Prevalence: GPA affects roughly 1–3 people per 100,000 in the United States, with nasal involvement present in up to 70 % of cases.
• Age: Most patients are diagnosed between 40 and 60 years old, but it can occur at any age, including childhood.
• Gender: Slight male predominance (≈55 % male).
• Ethnicity: Occurs worldwide; higher incidence reported in people of Northern European descent.

The disease is characterized by necrotizing granulomas (small areas of tissue death) and vasculitis that can damage the nasal septum, turbinates, and surrounding sinus structures, leading to chronic sinus disease, nosebleeds, and structural deformities.

Symptoms

Because GPA is a systemic disease, symptoms may be limited to the nose or involve other organs (lungs, kidneys, skin, etc.). The nasal‑focused symptom list includes:

Upper Respiratory Tract Symptoms

• Chronic sinusitis: Persistent nasal congestion, facial pressure, and post‑nasal drip that does not improve with usual treatments.
• Recurrent epistaxis (nosebleeds): Often painless, may be frequent or severe.
• Septal perforation: A hole or thinning in the nasal septum that can cause crusting, whistling sounds when breathing, and a “saddle‑nose” deformity.
• Ulcerated or crusted lesions: Painful or painless sores inside the nostrils, sometimes with a foul odor.
• Loss of smell (anosmia) or reduced sense of taste.
• Ear involvement: Middle‑ear effusion, hearing loss, or tinnitus due to eustachian tube dysfunction.

Systemic Symptoms (May accompany nasal disease)

• Fever, night sweats, unexplained weight loss.
• Joint or muscle aches.
• Chest pain, cough, or shortness of breath (lung involvement).
• Blood in urine, swelling of ankles (kidney involvement).
• Skin lesions such as palpable purpura or livedo reticularis.

Causes and Risk Factors

Underlying Cause

GPA is an autoimmune vasculitis. The exact trigger is unknown, but the immune system mistakenly attacks its own blood vessel walls, leading to inflammation and granuloma formation.

Key Risk Factors

• ANCA antibodies: Over 90 % of patients have anti‑neutrophil cytoplasmic antibodies (c‑ANCA, usually directed against proteinase‑3). Presence of c‑ANCA is a strong diagnostic clue but not a cause.
• Genetic predisposition: Certain HLA‑DPB1 and HLA‑DRB1 alleles increase susceptibility.
• Environmental exposures: Silica dust, certain drugs (e.g., propylthiouracil, hydralazine), or infections have been linked to GPA onset, though causality is not proven.
• Age & sex: Middle‑aged adults, especially men, have a higher incidence.
• Smoking: May increase risk of severe respiratory involvement.

Diagnosis

Clinical Evaluation

Diagnosis begins with a thorough history and physical examination, focusing on nasal findings (crusting, perforation, ulceration) and any systemic signs.

Laboratory Tests

• ANCA testing: c‑ANCA (PR3‑ANCA) is positive in ~80–90 % of generalized GPA cases.
• Complete blood count (CBC) – may show anemia or leukocytosis.
• Renal function panel – creatinine, BUN.
• Inflammatory markers – ESR and CRP usually elevated.

Imaging Studies

• CT of sinuses: Reveals mucosal thickening, bone erosion, or septal perforation.
• Chest X‑ray or CT: Looks for nodules, cavitations, or infiltrates if lung disease is suspected.

Biopsy (Definitive Test)

Histopathology from nasal mucosa, sinus tissue, or lung/renal lesions showing necrotizing granulomatous inflammation and vasculitis confirms the diagnosis. Though invasive, a biopsy is the gold standard because it distinguishes GPA from infections or other autoimmune disorders.

Diagnostic Criteria

Most clinicians use the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) classification criteria, which combine clinical features, ANCA status, and biopsy results to give a weighted score; ≥5 points indicates GPA.

Treatment Options

Induction Therapy (Rapid disease control)

Goal: achieve remission within 4–6 weeks.

• High‑dose glucocorticoids (e.g., prednisone 1 mg/kg daily, tapering over months).
• Immunosuppressive agents (choose one):
  • Rituximab 375 mg/m² weekly ×4 weeks (preferred for many patients; similar efficacy to cyclophosphamide with fewer long‑term toxicities). [NEJM 2015]
  • Cyclophosphamide IV (15 mg/kg every 2‑3 weeks) or oral (2 mg/kg daily) for 3–6 months.

Maintenance Therapy (Prevent relapse)

• Rituximab (500 mg IV every 6 months for 2–5 years) or
• Azathioprine 2 mg/kg/day, or
• Mycophenolate mofetil 1–1.5 g twice daily.
• Low‑dose prednisone (≤10 mg/day) is usually continued for the first year.

Adjunctive Measures for Nasal Disease

• Topical saline irrigation – reduces crusting and promotes mucosal healing.
• Intranasal corticosteroid sprays (e.g., mometasone) to lessen local inflammation.
• Antibiotic prophylaxis if chronic sinus infection develops (often culture‑directed).
• Surgical debridement in severe necrotic disease or to repair septal perforation.

Lifestyle & Supportive Care

• Vaccinations (influenza, pneumococcal, COVID‑19) – essential because immunosuppression raises infection risk.
• Calcium & vitamin D supplementation plus bone‑density monitoring (steroids increase osteoporosis risk).
• Regular eye exams if using high‑dose steroids.

Living with Wegener’s Granulomatosis (Nasal)

Daily Management Tips

• Moisturize the nasal passages – use saline sprays 2–4× daily, especially in dry climates.
• Gentle nasal hygiene – avoid aggressive blowing; use soft tissues and apply a thin layer of petroleum jelly to prevent crust formation.
• Monitor medication side effects – keep a log of symptoms such as new “moon face,” mood changes, or infections.
• Stay hydrated – adequate fluid intake helps keep mucus thin.
• Follow up regularly – rheumatology visits every 1–3 months during induction, then every 3–6 months for maintenance.
• Maintain a healthy weight – steroids can cause weight gain; balanced diet and moderate exercise help.
• Stress management – chronic disease can be emotionally taxing; consider counseling or support groups.

When to Call Your Doctor

Contact your rheumatologist or ENT specialist promptly if you notice new or worsening sinus pain, increasing nosebleeds, new skin lesions, coughing up blood, or changes in urine output.

Prevention

Because GPA’s exact cause is unknown, specific primary prevention is limited. However, you can lower the risk of disease flare‑ups and secondary complications:

• Adhere strictly to prescribed immunosuppressive regimen.
• Avoid tobacco smoke and occupational silica exposure.
• Stay current on vaccinations (influenza, pneumococcal, COVID‑19, hepatitis B).
• Promptly treat respiratory infections – they can trigger relapses.
• Limit use of drugs known to induce ANCA‑associated vasculitis (e.g., propylthiouracil) unless absolutely necessary.

Complications

If untreated or inadequately controlled, nasal GPA can lead to:

• Permanent septal perforation → saddle‑nose deformity, chronic crusting.
• Chronic sinusitis with bacterial colonization → mucocele formation or osteomyelitis.
• Upper airway obstruction – rare but possible from extensive granulomatous tissue.
• Systemic spread – lung hemorrhage, glomerulonephritis, peripheral neuropathy, and life‑threatening vasculitis.
• Medication toxicity – cyclophosphamide can cause bladder toxicity, infertility; long‑term steroids cause osteoporosis, diabetes, cataracts.
• Infection – immunosuppression raises risk for bacterial, viral, fungal infections (including opportunistic Pneumocystis jirovecii).

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases, American College of Rheumatology, European Alliance of Associations for Rheumatology, Cleveland Clinic, New England Journal of Medicine 2015;373:2064‑76, WHO.

```